Evidence map›Paper›PMID 37070748›Full record

ArticleMicrobial biotechnology2023

Towards the microbial home: An overview of developments in next-generation sustainable architecture.

Rachel Armstrong

Abstract readEditorial
In one paragraph

Article in Microbial biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Advanced Electroanalysis for Electrosynthesis.ACS organic & inorganic Au · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Rachel ArmstrongDepartment of Architecture, KU Leuven, Ghent, Campus Sint-Lucas, Belgium.ORCID 0000-0002-3516-6815

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Disruptive innovation is needed to raise the threshold of sustainable building performance, so that our buildings improve on net zero impacts and have a life-promoting impact on the natural world. This article outlines a new approach to next-generation sustainable architecture, which draws on the versatile metabolisms of microbes as a platform by incorporating microbial technologies and microbially produced materials into the practice of the built environment. The regenerative architecture arising from these interventions includes a broad range of advances from using new materials, to creating bioreceptive surfaces that promote life, and providing green, bio-remediating energy from waste. Such innovations are presently reaching the marketplace as novel materials like Biocement® with lower embodied carbon than conventional materials that adopt microbially facilitated processes, and as novel utilities like PeePower® that transforms urine into electrical energy and bioreactor-based building systems such as the pioneering BIQ building in Hamburg. While the field is still young, some of these products (e.g. mycelium biocomposites) are poised for uptake by the public-private economic axis to become mainstream within the building industry. Other developments are creating new economic opportunities for local maker communities that empower citizens and catalyse novel vernacular building practices. In particular, the activation of the microbial commons by the uptake of microbial technologies and materials through daily acts of living, 'democratises' resource harvesting (materials and energy) in ways that sustain life, and returns important decisions about how to run a home back to citizens. This disruptive move re-centres the domestic-commons economic axis to the heart of society, setting the stage for new vernacular architectures that support increasingly robust and resilient communities.

Indexed as

Conservation of Natural ResourcesSustainable Development

Identifiers

PMID37070748
PMCPMC10221549

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.